Take this short 5-question quiz to find out what you know--or, what you may have missed--about the latest developments in COPD.
Decrease in BMI Linked to Increased Risk for Severe Exacerbations, All-Cause Mortality in COPD
Among persons with COPD whose BMI decreased over a 4-year follow-up, mortality risk rose 70% compared with those whose BMI remained the same, researchers reported.
Tezepelumab for COPD Moves into Phase 3 Planning
Tezepelumab, a TSLP inhibitor, reduced COPD exacerbations in individuals with moderate/very severe COPD, regardless of baseline BEC and inflammatory drivers, Amgen said.
AstraZeneca Launches Phase 3 THARROS Trial of Breztri to Reduce Cardiopulmonary Events in COPD
THARROS is the first phase 3 RCT to evaluate an inhaled triple combination therapy for reduction of adverse cardiopulmonary events in people with COPD, says AstraZeneca.
Boehringer Ingelheim Will Cap Out of Pocket Costs for Inhalers at $35 per Month
The monthly out of pocket cap applies to all BI inhalers and goes into effect on June 1, 2024.
Impact of Regular Exercise on Hospitalization in Patients with COPD: Daily Dose
Your daily dose of the clinical news you may have missed.
FDA Accepts Dupilumab sBLA for Priority Review for Treatment of COPD with Type 2 Inflammation
A PDUFA date of June 27, 2024 has been set for approval of a 6th dupilimab indication - as add-on therapy for individuals with COPD and eosinophilic inflammation.